Rama appeals to the UN Assembly: Turn your eyes to cyber security, Albania was attacked by Iran
COVID in Albania/ The Ministry of Health gives the important announcement: What has happened in the last 24 hours
"The Third World War has already started", the well-known Russian figure sounds the alarm: Nuclear catastrophe...
Oil is 'flying' again/ the Transparency Board changes prices again, this is how much fuel will be sold
The head of SPAK warns of sensational arrests among the corrupt, reveals that special prosecutors and BKH agents are cooperating with 20 joint investigative teams from EU countries
From the suspension of "Air Albania", to the withdrawal of doctors from the Fier hospital and the hostage-taking of the Namazgja Mosque, how did Edi Rama's attitude towards the Gülenists change after Erdogan began withdrawing investments in Albania
Here are Edi Rama's 5 points for Erdogan, from the massacre of Gülen's schools, to the purchase of 40 million euros of drones from the son-in-law of the Turkish Sultan
The American attitude to the man of Mali with Gropa changes, Yuri Kim, a flash visit to the spy Ilir Metaj, the former President distances himself from "non grata" Sali Berisha
"An increase in infections is expected in the winter"/ BioNTech and Pfizer make the unexpected decision
Written by SOT.COM.AL 8 Gusht 2022
BioNTech and Pfizer have announced that they will begin a clinical trial of a vaccine tailored to the Omicron subvariants, BA.4 and BA.5, as the German company anticipates an increase in demand at the end of the year.
The company missed second-quarter sales and profit expectations after the European Commission renegotiated its Covid vaccine contract.
Second-quarter sales were 3.2 billion euros, compared with analysts' average estimate of 4 billion euros, and adjusted earnings per share were 6.87 euros, below the consensus forecast of 7.27 euros. The net profit in this period was 1.7 billion euros.
However BioNTech reiterated its full guidance for annual revenue between 13 billion and 17 billion euros, because doses planned for delivery in the second quarter and early third quarter will now be spread over the third and fourth quarters.
BioNTech CEO U?ur ?ahin said the company was expanding its range of anti-Covid products. BioNTech has produced doses of its first Omicron vaccine, for the BA subvariant. 1, since spring and is ready for delivery whenever it is approved by a regulator. The company expects to be able to start shipping vaccines for the BA.4 and BA.5 subvariants as early as October, if it receives approval from regulatory agencies.
Özlem Türeci, chief medical officer, said that data from studies and experiments in mice showed that vaccines tailored to the BA.4 and BA.5 subvariants elicited a stronger immune response against these variants and all other Omicron subvariants.
The European Medicines Agency will request clinical data for new vaccines against BA.4 and BA subvariants. 5, while the US Food and Drug Administration has said it would be willing to approve the initiative while trials are ongoing.